This purpose of this clinical trial is to evaluate the safety, tolerability and
anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial
includes participants with previously treated unresectable or metastatic cutaneous
melanoma (CM) or synovial sarcoma (SS).
Additional locations may be listed on ClinicalTrials.gov for NCT06946225.
Locations matching your search criteria
United States
Texas
Houston
M D Anderson Cancer CenterStatus: Active
Name Not Available
This clinical trial is a multi-center, open-label, non-comparative Phase 1 a/b trial to
assess the safety, tolerability, and anti-tumor activity of the combination of IMA203 and
mRNA-4203 in HLA-A*02:01 positive patients with previously treated, unresectable or
metastatic cutaneous melanoma (CM) and synovial sarcoma (SS).
Lead OrganizationImmatics US, Inc.